TENX (Tenax Therapeutics) Interest Expense: $0.00 Mil (TTM As of Mar. 2026)

What is Tenax Therapeutics Interest Expense?

Tenax Therapeutics TENX +5.17% 22 Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Tenax Therapeutics's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Tenax Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -16.57 Mil. Tenax Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Tenax Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Tenax Therapeutics (NAS:TENX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tenax Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-16.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.00 Mil.

Tenax Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Tenax Therapeutics had no long-term debt ⁽¹⁾.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Tenax Therapeutics Inc has no debt.

Tenax Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Tenax Therapeutics's Interest Expense can be seen below:

Tenax Therapeutics Interest Expense Chart

Tenax Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.00

-0.02

0.00

Tenax Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

22GF Score

Tenax Therapeutics Inc TENX

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tenax Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $0.00 Mil mean?

Tenax Therapeutics (TENX) has a Interest Expense of $0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tenax Therapeutics and its competitors.

Is Tenax Therapeutics' Interest Expense too high?

Tenax Therapeutics' current Interest Expense is $0.00 Mil. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.

How does Tenax Therapeutics' Interest Expense compare to RCKT and AVIR?

Tenax Therapeutics' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tenax Therapeutics and its competitors. Tenax Therapeutics's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tenax Therapeutics stock overvalued right now?

Tenax Therapeutics (TENX) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Tenax Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies RCKT AVIR VNDA DMAC OABI PRLD UPB LXEO CYDY PROK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges YBO0:Germany

Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517

Website https://www.tenaxthera.com

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

22GF Score

Get the complete analysis for TENX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.26

Price

View TENX Analysis

See Interest Expense data for all stocks →